Abbott Reports Strong Second Quarter Results Equities.com Abbott is partnering on the development of a novel, next-generation antibody, daclizumab, which is currently in Phase 3 clinical trials for MS. Additionally, Abbott recently announced positive results from a Phase 3 trial evaluating levodopa-carbidopa ... |
